Nuvation Bio Inc. (NUVB)Healthcare | Biotechnology | New York, United States | NYSE
5.08 USD
+0.27
(5.613%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.06 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:57 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★★★ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:15 a.m. EDT
NUVB remains a high-risk, high-reward biotech play defined by cash-flow challenges but exceptional long-term catalyst potential. The stock has staged a technical recovery from April lows, with strong analyst consensus (Strong Buy) and significant institutional support via analyst ratings. While the short-term technicals show a bottoming pattern supported by buying pressure, the lack of dividends and negative cash flow mean valuation is entirely asset-driven on the long side, making it a speculative hold suitable only for high-risk portfolios positioning for the next drug approval or major regulatory milestone. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.139563 |
| AutoETS | 0.143908 |
| AutoARIMA | 0.143909 |
| AutoTheta | 0.181210 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 37.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.082 |
| Excess Kurtosis | -1.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.896 |
| Revenue per Share | 0.184 |
| Market Cap | 1,766,243,968 |
| Forward P/E | -35.03 |
| Beta | 1.61 |
| Website | https://www.nuvationbio.com |
As of April 19, 2026, 1:15 a.m. EDT: Options data shows a significant long-side call flow bias. In the near term (May 2026), there is notable volume at the 7.5 strike (211 vol), suggesting bullish positioning above current price. Longer dated options (Jan 2027 and beyond) show heavy OI concentration in out-of-the-money calls (10.0 strike) combined with put support, but the call volume dominates recent activity. Put volume is relatively light in the near term (May/June) compared to deeper time frames, indicating the primary sentiment is directional upside speculation rather than immediate downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5656567 |
| Address1 | 1,500 Broadway |
| Address2 | Suite 1401 |
| All Time High | 15.23 |
| All Time Low | 0.95 |
| Ask | 5.09 |
| Ask Size | 1,800 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,824,670 |
| Average Daily Volume3 Month | 4,657,824 |
| Average Volume | 4,657,824 |
| Average Volume10Days | 2,824,670 |
| Beta | 1.61 |
| Bid | 5.06 |
| Bid Size | 3,400 |
| Board Risk | 8 |
| Book Value | 0.882 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.08 |
| Current Ratio | 6.95 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.1 |
| Day Low | 4.85 |
| Debt To Equity | 21.896 |
| Display Name | Nuvation Bio |
| Earnings Call Timestamp End | 1,772,487,000 |
| Earnings Call Timestamp Start | 1,772,487,000 |
| Earnings Timestamp | 1,772,485,200 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -211,324,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.168 |
| Enterprise To Revenue | 20.723 |
| Enterprise Value | 1,303,523,200 |
| Eps Current Year | -0.24 |
| Eps Forward | -0.145 |
| Eps Trailing Twelve Months | -0.6 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.9078 |
| Fifty Day Average Change | 0.17219973 |
| Fifty Day Average Change Percent | 0.03508695 |
| Fifty Two Week Change Percent | 156.56567 |
| Fifty Two Week High | 9.75 |
| Fifty Two Week High Change | -4.67 |
| Fifty Two Week High Change Percent | -0.47897437 |
| Fifty Two Week Low | 1.57 |
| Fifty Two Week Low Change | 3.5099998 |
| Fifty Two Week Low Change Percent | 2.2356687 |
| Fifty Two Week Range | 1.57 - 9.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,598,448,600,000 |
| Float Shares | 237,040,495 |
| Forward Eps | -0.145 |
| Forward P E | -35.034485 |
| Free Cashflow | -115,776,248 |
| Full Exchange Name | NYSE |
| Full Time Employees | 298 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.85218 |
| Gross Profits | 53,604,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18667999 |
| Held Percent Institutions | 0.62239 |
| Implied Shares Outstanding | 347,685,831 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York. |
| Long Name | Nuvation Bio Inc. |
| Market | us_market |
| Market Cap | 1,766,243,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_639036735 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -204,627,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,766,244,021 |
| Number Of Analyst Opinions | 9 |
| Open | 4.9 |
| Operating Cashflow | -173,427,008 |
| Operating Margins | -0.81302 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 332 208 6102 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.39370042 |
| Post Market Price | 5.06 |
| Post Market Time | 1,776,470,221 |
| Previous Close | 4.81 |
| Price Eps Current Year | -21.166666 |
| Price Hint | 2 |
| Price To Book | 5.759637 |
| Price To Sales Trailing12 Months | 28.079298 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.671 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.27 |
| Regular Market Change Percent | 5.61331 |
| Regular Market Day High | 5.1 |
| Regular Market Day Low | 4.85 |
| Regular Market Day Range | 4.85 - 5.1 |
| Regular Market Open | 4.9 |
| Regular Market Previous Close | 4.81 |
| Regular Market Price | 5.08 |
| Regular Market Time | 1,776,456,002 |
| Regular Market Volume | 2,243,693 |
| Return On Assets | -0.23456 |
| Return On Equity | -0.53183997 |
| Revenue Growth | 6.331 |
| Revenue Per Share | 0.184 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 346,685,831 |
| Shares Percent Shares Out | 0.1402 |
| Shares Short | 48,734,624 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 46,863,929 |
| Short Name | Nuvation Bio Inc. |
| Short Percent Of Float | 0.22649999 |
| Short Ratio | 9.62 |
| Source Interval | 15 |
| State | NY |
| Symbol | NUVB |
| Target High Price | 20.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 12.33333 |
| Target Median Price | 12.0 |
| Total Cash | 529,211,008 |
| Total Cash Per Share | 1.522 |
| Total Debt | 66,940,000 |
| Total Revenue | 62,902,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.82315 |
| Two Hundred Day Average Change | 0.25684977 |
| Two Hundred Day Average Change Percent | 0.053253528 |
| Type Disp | Equity |
| Volume | 2,243,693 |
| Website | https://www.nuvationbio.com |
| Zip | 10,036 |